Market- Overview
The Global Joint Pain Injections Market is estimated to reach, growing at a CAGR of 6.8% during the forecast period (2022-2029).
A joint injection (intra-articular injection) is a medical procedure used to treat inflammatory joint disorders such as rheumatoid arthritis, psoriatic arthritis, gout, tendinitis, bursitis, Carpal Tunnel Syndrome, and osteoarthritis. A hypodermic needle is inserted into the afflicted joint, delivering a dosage of anti-inflammatory medication, the most frequent of which are corticosteroids. Because of its high viscosity, hyaluronic acid is sometimes used to replace bursa fluids. The procedure can also be done to remove excess fluid from the joint.
Market Dynamics
The growing prevalence of obesity in the population is expected to increase the use of these injections. Factors such as an increase in sedentary behaviour and an ageing population in both developed and developing countries are expected to increase the use of intra-articular injections. Furthermore, rising osteoarthritis and musculoskeletal disorders are expected to drive market growth.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/joint-pain-injection-market
An increase in prevalence of arthritis in the market will drive the market growth
The extension of the joint pain injections market is predicted to be influenced by rising incidences of joint pain in developed and emerging nations and the rapid development of injections that allow doctors to analyze the fundamental causes of pain and aid in reducing pain swiftly. The facet joint injections contain a portion of an anaesthetic drug, which numbs the muscles, ligaments, and articular capsules. Increased demand for non-surgical care has been identified as a key element promoting facet joint injections output during the predicted period. Furthermore, it is predicted to contribute to the total build-up of the facet joint injection during the evaluation time, improving the focus on effective pain relief.
Arthritis is the biggest cause of disability among adults in the United States, according to the Arthritis Foundation. Approximately 54 million people and 300,000 newborns and toddlers have arthritis or another rheumatic disease in the US. By 2040, more than 78 million people in the US would have been diagnosed with arthritis. In addition, osteoarthritis is the most common type of arthritis, affecting over 31 million people in the United States. The rising prevalence of arthritis is expected to raise demand for disease-modifying treatments, propelling the joint pain injections market during the forecast period.
Obesity is linked to various joint problems, particularly those affecting the knee, such as knee discomfort and osteoarthritis. Global obesity has tripled since 1975, according to a fact sheet provided by the World Health Organization (WHO). In 2016, 1.9 bn people were overweight, with over 650 million adults falling into this category. Furthermore, in 2017, approximately 41 million children under five were obese. According to the 2015-2016 National Health and Nutrition Examination Survey (NHANES), more than one out of every four children of Hispanic descent aged 2 to 19 had obesity, and nearly half of all adults had obesity.
Market Segmentation
By Product
- Pre-filled injections
- Vials
By Injection Type
- Corticosteroid Injections
- Hyaluronic Acid Injections
- Platelete Rich Plasma Injections
- Others
By Joint Type
- Knee and Ankle
- Hip
- Shoulder and Elbow
- Others
Competitive Landscape
The joint pain injections market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Anika Therapeutics Inc, Bioventus, Ferring Pharmaceuticals Inc, Sanofi SA, Pfizer Inc, Eli Lilly and Company, Flexion Therapeutics Inc, Teva Pharmaceuticals, Zimmer Biomet, Dr Reddy Laboratories.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the joint pain injections market globally. For instance, in July 2019, Teva Pharmaceutical Industries Ltd. declared the launch of 1% Sodium Hyaluronate in the US market following approval from the US FDA’s Center for Devices and Radiological Health. This product is used to treat pain associated with knee osteoarthritis.
Trending Reports
Orthopedic Casts and Splints Market
Orthopedic Regenerative Surgical Products Market
Pulse Electromagnetic Field Therapy Devices Market
About Us:
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions.
Media Contact:
Name: Sai Kiran
Company: DataM Intelligence
Contact No: +1 8774414866
Email us: info@datamintelligence.com